Biomarker-Based Lung Cancer Screening Eligibility: Implementation Considerations

Abstract

With the convergence of promising biomarkers for lung cancer risk stratifications, and the increasing need for better eligibility assessment for lung cancer low-dose CT (LDCT) screening, the elephant in the room now is whether and how the implementation of biomarker-based lung cancer screening eligibility can be successfully achieved. This brief commentary provides an outline of key considerations for biomarker implementations for LDCT eligibility assessment and possible mitigation strategies.